MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
MediciNova EV - Enterprise Value 2011-2026 | MNOV
Annual EV - Enterprise Value MediciNova
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.4 M | 58.7 M | 18.6 M | 101 M | 48.4 M | 202 M | 196 M | 293 M | 269 M | 164 M | 90.2 M | 84.6 M | 45.9 M | 32.4 M | 19.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 293 M | 18.6 M | 111 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
9.45 M | $ 0.89 | - | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
3.33 B | $ 22.2 | - | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
6.91 M | $ 15.9 | - | $ 50.8 M | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-4.88 M | $ 0.76 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
11.9 B | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Galapagos NV
GLPG
|
82.8 M | $ 27.86 | - | $ 2.69 B |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
11.8 B | $ 7.91 | - | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
1.26 B | $ 31.05 | - | $ 1.79 B | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
69.7 M | $ 8.44 | - | $ 76.2 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
-4.91 B | $ 101.57 | - | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
Immuron Limited
IMRN
|
-20.4 M | $ 0.81 | 0.3 % | $ 9.47 M |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
18.2 B | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
-5.18 M | $ 0.7 | - | $ 1.71 M | Canada |
 |
INmune Bio
INMB
|
12.3 M | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
1.07 B | $ 23.05 | - | $ 1.55 B | USA |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
259 M | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Jaguar Health
JAGX
|
57 M | $ 7.88 | - | $ 18.4 M | USA |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
944 M | $ 26.67 | - | $ 1.44 B | Britain |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Kamada Ltd.
KMDA
|
252 M | $ 8.11 | - | $ 260 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.98 | - | $ 4.91 M | Israel |
 |
Krystal Biotech
KRYS
|
8.08 B | $ 259.95 | - | $ 7.52 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
141 M | $ 12.42 | - | $ 1.65 B | Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
2.26 B | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Liquidia Corporation
LQDA
|
3.04 B | $ 38.15 | - | $ 3.28 B | USA |
 |
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
540 M | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |